The ECHELON-2 Trial: 5-year exploratory subgroup analyses of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A + CHP) vs CHOP in frontline treatment of pts with CD30-positive peripheral T-cell lymphoma Meeting Abstract
| Authors: | Horwitz, S. M.; Savage, K. J.; Illidge, T.; Plyer, S. P.; Advani, R.; Shustov, A. R.; Bartlett, N. L.; Pro, B.; Jacobsen, E. D.; Koch, R.; Eva, D. D.; Fanale, M. A.; Fenton, K.; Campana, F.; Dong, C.; Truemper, L. |
| Abstract Title: | The ECHELON-2 Trial: 5-year exploratory subgroup analyses of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A + CHP) vs CHOP in frontline treatment of pts with CD30-positive peripheral T-cell lymphoma |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736398800133 |
| DOI: | 10.1182/blood-2021-145124 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 135 -- Hybrid meeting, also took place online -- Source: Wos |
